The Patent Finder

Terms ending in 2032

Sandoz AG

Every in-force patent on Sandoz AG's record whose computed term ends in 2032, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 9,139,597Method for the Production of Ceftobiprole Medocaril
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 9,266,868Crystalline Form of Rivaroxaban Dihydrate
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 9,745,588Transcription Terminator Sequences
In force
 · High confidence
Sandoz AG and Boehringer Ingelheim RCV GmbH & Co. KGIn forceHigh confidence
US 9,458,146Crystalline Sodium Salt of an HIV Integrase Inhibitor
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 9,440,924Acetone Solvate of Ivabradine Hydrochloride
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 9,938,239Method For Preparing Silodosin
In force
 · High confidence
Sandoz AGIn forceHigh confidence
US 9,394,328Crystalline Dapagliflozin Hydrate
In force
 · High confidence
Sandoz AGIn forceHigh confidence
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited